Brachytherapy Plus EBRT for Intermediate-Risk Prostate Cancer Brachytherapy Plus EBRT for Intermediate-Risk Prostate Cancer
Questions persist about the benefits of combination therapy vs brachytherapy alone, despite findings of a new study, says Dr Gerald Chodak.Medscape Urology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - January 24, 2017 Category: Radiology Tags: Urology Commentary Source Type: news
Stockholm County Council, New Karolinska Solna and Elekta Sign Long-term Collaboration Agreement to Advance Cancer Care
STOCKHOLM, Sweden, Dec 30, 2016 -- (Healthcare Sales & Marketing Network) -- Elekta (EKTA-B.ST), Stockholm's County Council and New Karolinska Solna (NKS) have signed a 13-year collaboration agreement which focuses on innovation, joint research, and educa... Devices, Neurosurgery Elekta, radiation therapy, linear accelerator, brachytherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 30, 2016 Category: Pharmaceuticals Source Type: news
Salutaris lands FDA OK for radionuclide brachytherapy
Ophthalmic medical device developer Salutaris Medical Devices has received...Read more on AuntMinnie.com (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 20, 2016 Category: Radiology Source Type: news
National cancer group recommends Sirtex ’ s microspheres for metastatic colorectal cancer
Sirtex Medical (ASX:SRX) said yesterday that the National Comprehensive Cancer Network has recommended the company’s radioactive microspheres in its Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. The NCCN panel uniformly agreed that selective internal radiation therapy with yttrium-90 microspheres is an option for patients with metastatic, chemotherapy resistant colorectal cancer.
The recommendation was supported by the More retrospective analysis study, which included 600 patients with colorectal cancer. The data suggested that selective internal radiation therapy using Y-90 microsphe...
Source: Mass Device - December 13, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Sirtex Medical Source Type: news
iCAD to highlight Xoft clinical results at SABCS
Computer-aided detection (CAD) developer iCAD plans to highlight at the upcoming...Read more on AuntMinnie.comRelated Reading:
iCAD highlights breast cancer studies at RSNA 2016
iCAD taps new CFO
iCAD touts brachytherapy research at ASTRO 2016
iCAD president resigns
iCAD shows revenue decline in Q2 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 7, 2016 Category: Radiology Source Type: news
iCAD highlights breast cancer studies at RSNA 2016
Computer-aided detection (CAD) developer iCAD is touting two studies at RSNA...Read more on AuntMinnie.comRelated Reading:
iCAD taps new CFO
iCAD touts brachytherapy research at ASTRO 2016
iCAD president resigns
iCAD shows revenue decline in Q2
iCAD adds to customer base (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 28, 2016 Category: Radiology Source Type: news
AccuBoost points to study in Brachytherapy
Women's health firm AccuBoost is directing attention to a recent study in Brachytherapy...Read more on AuntMinnie.comRelated Reading:
AccuBoost unveils new tech at ABS APBI school
AccuBoost adds to customer list
AccuBoost inks Ga. contract
ART wins Fla. contract
ART installs AccuBoost in Okla., Va. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 16, 2016 Category: Radiology Source Type: news
Augmenix scores reimbursement code for SpaceOar
Augmenix said today it won a category 1 current procedural terminology reimbursement code from the American Medical Association for periprostatic implantation of biodegradable material, covering its flagship SpaceOAR device.
The SpaceOar is designed to separate the prostate from the rectal wall during radiation treatment for prostate cancer, Augmenix said.
The device is delivered through a small needle as a liquid, which then solidifies into a soft gel that expands the space between the prostate and rectum during radiotherapy. The substance then liquefies and is absorbed and cleared from the body in the patient’s urine...
Source: Mass Device - November 9, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Urology Augmenix Inc. Source Type: news
Eckert & Ziegler posts 9-month financial results
Isotope technology firm Eckert & Ziegler has posted financial results for...Read more on AuntMinnie.comRelated Reading:
Eckert & Ziegler reports loss in Q4
Eckert & Ziegler to produce pancreatic cancer agent
Eckert & Ziegler warns of lower profit in 2013 report
Eckert & Ziegler posts modest sales uptick
Eckert & Ziegler acquires brachytherapy firm (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 4, 2016 Category: Radiology Source Type: news
Less than half of cervical cancer patients receive standard-of-care treatment
(University of Colorado Anschutz Medical Campus) University of Colorado Cancer Center study shows that only 44 percent of patients in a large, national sample received all three components of standard-of-care treatment for cervical cancer, most often lacking brachytherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2016 Category: Global & Universal Source Type: news
ASTRO: Brachytherapy Boost Tops EBRT for Prostate Ca (CME/CE)
(MedPage Today) -- But use has fallen despite potential benefits (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - October 3, 2016 Category: Endocrinology Source Type: news
Addition of EBT to brachytherapy does not produce superior PFS results
(NRG Oncology) NRG Oncology researchers reported that adding external radiation therapy to standard brachytherapy did not improve progression-free survival for men with intermediate-risk prostate cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 3, 2016 Category: Cancer & Oncology Source Type: news
ASTRO: Brachytherapy Enough for Mid-Risk Prostate Cancer (CME/CE)
(MedPage Today) -- Similar outcomes, fewer side effects vs external beam therapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 30, 2016 Category: Hematology Source Type: news
